North Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, as well as the Technical University Dortmund in an AI network for cancer medicine.
Teitur Trophics reports positive phase 1 data for Parkinson’s peptide
Latest NewsDanish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson’s disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the peptide into phase 2 testing in 2027.
Leyden Labs reveals RIGImmune acquisition with Phase 1 data
Latest NewsDutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year.
Inside exosomes: Nature’s drug carriers
Background, Latest NewsNext-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding immune reactions (seen with many viral vectors) or undesired organ accumulation (evidenced with LNPs in the liver). Scientists are now harnessing a technology that could overcome these hurdles by using vesicles that cells naturally produce: exosomes.
Pharvaris oral HAE drug cuts attacks by 83% in Phase 3
Latest NewsSwitzerland-based Pharvaris’ once-daily oral deucrictibant XR reduced hereditary angioedema (HAE) attacks by 83% versus placebo in a pivotal Phase 3 trial, putting the experimental prophylactic into roughly the same efficacy range as several leading injected treatments.
Novartis’ $12B Avidity bet suffers Phase 3 blow
Latest NewsNovartis has suffered another pipeline setback after del-desiran, an antibody-oligonucleotide conjugate acquired with Avidity Biosciences, failed to significantly improve hand function over placebo in the Phase 3 HARBOR study in myotonic dystrophy type 1.
Germany’s NRW state bets €200M on AI-powered cancer research
Latest NewsNorth Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, as well as the Technical University Dortmund in an AI network for cancer medicine.
Vaxdyn raises €11M Series A to test AMR vaccine
Latest NewsSpanish biotech Vaxdyn has raised an €11 million Series A to take K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii, into a first-in-human Phase 1 trial. Portuguese investor Biovance Capital led the round with a €4 million investment, joined by the European Innovation Council (EIC) Fund and the Impacto Andalusia fund managed by Arcano Partners.
BioInnovation Institute backs six startups with €8M
Latest NewsCopenhagen’s BioInnovation Institute (BII) is providing six early-stage companies with €1.3 million each in convertible loans, taking its total financing of each startup to €1.8 million.
New CEO took over the reins
AppointmentsAt the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer for nearly seven years.
Novartis’ Lp(a) drug misses Phase 3 endpoint
Latest NewsNovartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, despite successfully lowering the genetically driven cardiovascular risk factor.